A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 [brivanib] in combination with 5-fluorouracil/leucovorin [folinic acid] and irinotecan or oxaliplatin for patients with advanced or metastatic cancer

Trial Profile

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 [brivanib] in combination with 5-fluorouracil/leucovorin [folinic acid] and irinotecan or oxaliplatin for patients with advanced or metastatic cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2007

At a glance

  • Drugs Brivanib alaninate; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Gastrointestinal cancer
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Mar 2007 Status changed from recruiting to discontinued.
    • 07 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top